Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade
C Genova, C Dellepiane, P Carrega… - Frontiers in …, 2022 - frontiersin.org
In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been
revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against …
revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against …
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno …
S Hendry, R Salgado, T Gevaert… - Advances in anatomic …, 2017 - journals.lww.com
Assessment of the immune response to tumors is growing in importance as the prognostic
implications of this response are increasingly recognized, and as immunotherapies are …
implications of this response are increasingly recognized, and as immunotherapies are …
Association of machine learning–based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with …
Importance Currently, predictive biomarkers for response to immune checkpoint inhibitor
(ICI) therapy in lung cancer are limited. Identifying such biomarkers would be useful to refine …
(ICI) therapy in lung cancer are limited. Identifying such biomarkers would be useful to refine …
Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study
Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic
responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this …
responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this …
Pembrolizumab after completion of locally ablative therapy for oligometastatic non–small cell lung cancer: a phase 2 trial
JM Bauml, R Mick, C Ciunci, C Aggarwal… - JAMA …, 2019 - jamanetwork.com
Importance Patients with oligometastatic non–small cell lung cancer (NSCLC) may benefit
from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies …
from locally ablative therapy (LAT) such as surgery or stereotactic radiotherapy. Prior studies …
Vaccines for established cancer: overcoming the challenges posed by immune evasion
Therapeutic vaccines preferentially stimulate T cells against tumour-specific epitopes that
are created by DNA mutations or oncogenic viruses. In the setting of premalignant disease …
are created by DNA mutations or oncogenic viruses. In the setting of premalignant disease …
[HTML][HTML] The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non–small cell lung cancer
A malignant tumor is not merely an accumulation of neoplastic cells, but constitutes a
microenvironment containing endothelial cells, fibroblasts, structural components, and …
microenvironment containing endothelial cells, fibroblasts, structural components, and …
Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non–small cell lung cancer
Purpose: The presence of a high degree of tumor-infiltrating lymphocytes (TIL) has been
proven to be associated with outcome in patients with non–small cell lung cancer (NSCLC) …
proven to be associated with outcome in patients with non–small cell lung cancer (NSCLC) …
Spatial density and distribution of tumor-associated macrophages predict survival in non–small cell lung carcinoma
The respective antitumoral and protumoral roles of M1 and M2 tumor-associated
macrophages (TAM) typify the complexity of macrophage function in cancer. In lung cancer …
macrophages (TAM) typify the complexity of macrophage function in cancer. In lung cancer …
[HTML][HTML] Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
Anti-programmed cell death protein 1 (PD-1) agents have become the standard of care for
platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) …
platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) …